Allarity Therapeutics is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP^®) technology to refine patient selection and improve clinical outcomes. Publicly traded on the NASDAQ, Allarity (ALLR) and is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.